Jeremy Chadwick Sells 3,919 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 3,919 shares of Kymera Therapeutics stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $334,290.70. Following the completion of the transaction, the chief operating officer directly owned 73,810 shares in the company, valued at $6,295,993. The trade was a 5.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $83.52 on Friday. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The stock has a market cap of $6.82 billion, a P/E ratio of -22.70 and a beta of 2.20. The firm has a fifty day moving average price of $78.75 and a 200 day moving average price of $66.52.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. During the same period in the previous year, the company posted ($0.88) earnings per share. Kymera Therapeutics’s quarterly revenue was down 60.8% on a year-over-year basis. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its stake in shares of Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC boosted its holdings in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares in the last quarter. Osaic Holdings Inc. grew its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the period. Finally, Bessemer Group Inc. grew its position in Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares during the period.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts across Q1–Q4 2026 (small EPS improvements) and reiterated a Buy with a $134 target — this reduces short‑term downside expectations and supports investor interest. HC Wainwright note
• Positive Sentiment: Recent analyst target increases and bullish notes (including UBS coverage and other upgrades) signal renewed conviction in Kymera’s pipeline and cash runway; these reports are a constructive counterbalance to selling. UBS bullish note
• Positive Sentiment: Some outlets raised Kymera price targets (example: a recent note raising a target to $100), which can attract buyers and provide technical support. Price target update
• Neutral Sentiment: Technical/context: KYMR remains above its 200‑day moving average with elevated volatility (beta ~2.2); analyst consensus targets sit well above the current price, which can amplify both rallies and pullbacks. Market data
• Neutral Sentiment: Institutional activity shows modest position changes among several managers; current flows are not large enough to decisively move the stock by themselves. Institutional holdings
• Negative Sentiment: Large insider selling: Director Bruce Booth sold 81,866 shares (~$7.38M at ~ $90), a substantial, visible transaction that can be perceived as profit‑taking and pressuring the stock. Booth Form 4
• Negative Sentiment: Multiple senior executives (CFO, COO and others) disclosed sales across March 2–4, trimming positions by a few percent each—these repeated insider sales amplify short‑term negative sentiment despite company‑level explanations (e.g., diversification or tax/liquidity needs). Insider filings
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss and steep revenue decline year‑over‑year, which remains a fundamental drag on the stock until upcoming clinical milestones or revenue inflection points arrive. Earnings report

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Barclays increased their price target on Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a report on Tuesday, January 27th. Jefferies Financial Group boosted their price objective on shares of Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Citigroup raised their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Bank of America lifted their target price on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.